You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

intermediate-2 and high risk myelodysplastic syndromes (MDS)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MDS Trial (Decitabine/Cedazuridine, Magrolimab)

Not yet recruiting
  • Myelodysplastic Syndromes
  • (no location specified)
Apr 18, 2023

Acute Myeloid Leukemia, Myelodysplastic Tumor Trial (Magrolimab, 7+3, CPX-351)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Neoplasm
  • (no location specified)
Apr 24, 2023

Azacitidine in International Prognostic Scoring System

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
    • Hefei, Anhui, China
    • +16 more
    Sep 6, 2022

    Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)

    Recruiting
    • Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
    • Ocala, Florida
    • +3 more
    Jan 30, 2023

    Myelodysplastic Syndrome Trial in France (Azacitidine)

    Completed
    • Myelodysplastic Syndrome
    • Amiens, France
    • +20 more
    Dec 24, 2021

    MDS Trial (Imetelstat)

    Available
    • Myelodysplastic Syndromes
    • (no location specified)
    Jun 30, 2023

    Anemia, MDS, Chronic Myelomonocytic Leukemia Trial in France, United States (Sotatercept)

    Completed
    Has Results
    • Anemia
    • +5 more
    • Denver, Colorado
    • +19 more
    Oct 20, 2022

    MDS Trial in Bronx (Pyrimethamine)

    Withdrawn
    • Myelodysplastic Syndromes
    • Bronx, New York
      Montefiore Medical Center
    Sep 15, 2021

    MDS, MDS, Thrombocytopenia Trial (Placebo, Romiplostim)

    Completed
    Has Results
    • MDS
    • +2 more
    • Placebo
    • Romiplostim
    • (no location specified)
    Nov 4, 2022

    MDS Trial in Miami, New York (50 gm CIVI/24 hours x 5 days every 4 week)

    Recruiting
    • Myelodysplastic Syndromes
    • 50 gm CIVI/24 hours x 5 days every 4 week
    • Miami, Florida
    • +1 more
    Jul 6, 2022

    Lower Risk MDS Per IPSS-R Trial (Luspatercept)

    Not yet recruiting
    • Lower Risk MDS Per IPSS-R
    • (no location specified)
    Jun 21, 2023

    MDS Trial in Houston (Luspatercept)

    Not yet recruiting
    • Myelodysplastic Syndromes
    • Houston, Texas
      M D Anderson Cancer Center
    Nov 2, 2023

    Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Suzhou

    Recruiting
    • Allogeneic Hematopoietic Stem Cell Transplantation
    • +2 more
    • VEN+AZA+Modified BUCY
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Apr 10, 2023

    MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral

    Not yet recruiting
    • Myelodysplastic Syndromes
    • +3 more
    • Subcutaneous azacitidine
    • Oral decitabine/cedazuridine
    • Newcastle, New South Wales, Australia
      Calvary Mater Newcastle
    May 29, 2023

    MDS, CMML, AML Trial in Canada, United States (SGI-110)

    Completed
    • MDS
    • +2 more
    • Scottsdale, Arizona
    • +15 more
    Apr 16, 2021

    Anemia Trial (Luspatercept)

    Not yet recruiting
    • Anemia
    • Luspatercept
    • (no location specified)
    May 26, 2023

    MDS Trial in Worldwide (Oral Azacitidine, Placebo for Oral Azacitidine)

    Not yet recruiting
    • Myelodysplastic Syndromes
    • Oral Azacitidine
    • Placebo for Oral Azacitidine
    • Buenos Aires, Argentina
    • +1 more
    Aug 1, 2022

    MDS Trial in Seoul (cyclophosphamide, fludarabine, and antithymocyte globulin)

    Active, not recruiting
    • Myelodysplastic Syndromes
    • cyclophosphamide, fludarabine, and antithymocyte globulin
    • Seoul, Korea, Republic of
      Asan Medical Center, University of Ulsan College of Medicine
    Oct 19, 2023

    AML, MDS, Old Age; Debility Trial in Suzhou (Azacitidine, all trans retinoic acid)

    Recruiting
    • AML
    • +3 more
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Dec 27, 2021

    High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,

    Active, not recruiting
    Has Results
    • High Risk Myelodysplastic Syndrome
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 11, 2022

    MDS Trial run by the National Cancer Institute (NCI) (KPT-8602, Inqovi)

    Not yet recruiting
    • Myelodysplastic Syndromes
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jun 30, 2023

    MDS, Myeloproliferative Tumor, Anemia Trial in Tampa (Luspatercept)

    Recruiting
    • Myelodysplastic Syndromes
    • +2 more
    • Tampa, Florida
      Moffitt Cancer Center
    Feb 16, 2023

    MDS Trial in Worldwide (MBG453, Placebo, Hypomethylating agents)

    Active, not recruiting
    • Myelodysplastic Syndromes
    • Duarte, California
    • +46 more
    Jan 20, 2023

    Myelodysplastic Syndrome (MDS) Trial in Worldwide (sabatolimab, azacitidine, venetoclax)

    Active, not recruiting
    • Myelodysplastic Syndrome (MDS)
    • Brasschaat, Belgium
    • +9 more
    Jan 19, 2023

    Acute Myeloid Leukemia, MDS Trial in Hangzhou (Decitabine for Injection, VENCLYXTO)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • Myelodysplastic Syndromes
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, College of Medicine, Zhejiang Uni
    Sep 18, 2023